Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Most extracted claims concern patent-expiration and related filings, which are not supported by the provided FDA-approved label sections. Only the identification that Keytruda is pembrolizumab and the monoclonal antibody characterization are supported by the available label text; one claim is partially supported.
Category Scores
Accurate Statements
Keytruda is also known as pembrolizumab.
11 DESCRIPTION ("KEYTRUDA (pembrolizumab) injection")
Keytruda (pembrolizumab) is a monoclonal antibody used in the treatment of various types of cancer.
11 DESCRIPTION supports monoclonal-antibody characterization ("humanized monoclonal IgG4... antibody"). The 'used in the treatment of various types of cancer' portion is not supported by the provided label excerpt.
Unsupported Statements
The original U.S. Patent No. 8,233,356 for pembrolizumab expired in September 2022.
Patent-expiration details are not present in the provided FDA label sections.
The U.S. Patent and Trademark Office lists several patents related to pembrolizumab with varying expiry dates.
USPTO/patent listing details are not included in the provided FDA label sections.
The manufacturer Bristol-Myers Squibb has filed multiple follow-up patents for pembrolizumab that extend patent protection for the medication.
Patent-filing/extension details are not part of the provided FDA label sections.
The patent for pembrolizumab 100 mg injectable solution is set to expire in March 2038.
No patent-expiry timeline is present in the provided FDA label sections.
Other formulations or compositions of pembrolizumab may have different patent expiry dates.
Comparisons of patent expiry by formulation/composition are not supported by the provided FDA label sections.
Contradictions
Important Omissions
Any FDA label-aligned claims regarding approved indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, or safety monitoring are not addressed in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided extracted claims are primarily about patents rather than FDA-labeled clinical safety, dosing, contraindications, or administration; no direct safety instructions or dosing errors are stated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Unaligned
Primary Issue
Multiple claims are about patent expiration/filings, which are not supported by the provided FDA-approved label sections.
Suggested Improvement
Limit claims to FDA label-supported content (e.g., product identity and formulation description in the provided sections) and remove patent-related statements unless the specific FDA label text includes them.